Bal Pharma Valuation

Is BALPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BALPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BALPHARMA (₹134.5) is trading below our estimate of fair value (₹1309.57)

Significantly Below Fair Value: BALPHARMA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BALPHARMA?

Key metric: As BALPHARMA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BALPHARMA. This is calculated by dividing BALPHARMA's market cap by their current earnings.
What is BALPHARMA's PE Ratio?
PE Ratio28.2x
Earnings₹76.63m
Market Cap₹2.16b

Price to Earnings Ratio vs Peers

How does BALPHARMA's PE Ratio compare to its peers?

The above table shows the PE ratio for BALPHARMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average58x
524828 BDH Industries
18.2xn/a₹1.8b
VAISHALI Vaishali Pharma
183.4xn/a₹2.0b
506128 Parnax Lab
14.4xn/a₹1.7b
532384 Tyche Industries
15.8xn/a₹1.9b
BALPHARMA Bal Pharma
28.2xn/a₹2.2b

Price-To-Earnings vs Peers: BALPHARMA is good value based on its Price-To-Earnings Ratio (28.2x) compared to the peer average (58x).


Price to Earnings Ratio vs Industry

How does BALPHARMA's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$71.82m
524652 Ind-Swift
2xn/aUS$13.29m
No more companies available in this PE range
BALPHARMA 28.2xIndustry Avg. 32.2xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BALPHARMA is good value based on its Price-To-Earnings Ratio (28.2x) compared to the Indian Pharmaceuticals industry average (32.2x).


Price to Earnings Ratio vs Fair Ratio

What is BALPHARMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BALPHARMA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BALPHARMA's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies